Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors

NCT01782443 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01782443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01782443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
February 13, 2013
Completion date
December 26, 2021
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumor